General Information of the Drug (ID: M6APDG04142)
Name
Tarextumab
Status
Phase 2
TTD Drug ID
D01QLP
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Notch-2 receptor (NOTCH2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Notch-2 receptor (NOTCH2) is a therapeutic target for Tarextumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tarextumab through regulating the expression of Notch-2 receptor (NOTCH2). [1], [2]
Notch-3 receptor (NOTCH3)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Notch-3 receptor (NOTCH3) is a therapeutic target for Tarextumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tarextumab through regulating the expression of Notch-3 receptor (NOTCH3). [3], [4]
References
Ref 1 Therapeutic targeting m6A-guided miR-146a-5p signaling contributes to the melittin-induced selective suppression of bladder cancer. Cancer Lett. 2022 May 28;534:215615. doi: 10.1016/j.canlet.2022.215615. Epub 2022 Mar 9.
Ref 2 The manganese superoxide dismutase mimetic, M40403, protects adult mice from lethal total body irradiation. Free Radic Res. 2010 May;44(5):529-40. doi: 10.3109/10715761003649578.
Ref 3 N?-Methyladenosine Landscape of Glioma Stem-Like Cells: METTL3 Is Essential for the Expression of Actively Transcribed Genes and Sustenance of the Oncogenic Signaling. Genes (Basel). 2019 Feb 13;10(2):141. doi: 10.3390/genes10020141.
Ref 4 Clinical pipeline report, company report or official report of Oncotelic.